You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮製藥-B(01672.HK)新冠片劑年產能擴大至1億片
阿思達克 01-03 09:22
歌禮製藥-B(01672.HK)公布,擴大利托那韋口服片劑產能,並公布治療新型冠狀病毒(SARS-CoV-2)感染的口服直接抗新冠病毒研發管線。公司抗新冠肺炎藥物管線目前包括已上市的利托那韋口服片劑(100 mg);口服聚合(酉每)(RdRp)抑制劑ASC10;口服蛋白(酉每)(3CLpro)抑制劑ASC11。 低劑量利托那韋口服片劑(100 mg)作為多種抗病毒蛋白(酉每)抑制劑的藥代動力學增強劑,是口服直接抗新冠病毒藥物Paxlovid(Nirmatrelvir+利托那韋)的組成之一。公司計劃在全球多個國家進行利托那韋口服片劑仿製藥藥品註冊申請。利托那韋口服片劑年產能已擴大至1億片,未來根據市場需求可以進一步快速擴大。 此外,ASC11是靶點為蛋白(酉每)(3CLpro)的口服直接抗新冠病毒候選藥物,與公司已上市的利托那韋口服片劑聯用治療新型冠狀病毒感染。ASC11是完全自主研發的候選藥物,擁有全球知識產權和商業化權益。公司計劃於2022年下半年向中國、美國等國家提交臨床試驗申請。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account